Eli Lilly announced in Indianapolis, Indiana, on November 9 that its once-daily pill Foundayo, or orforglipron, reduced obstructive sleep apnea severity in two Phase 3 studies of adults with moderate-to-severe disease and obesity or overweight. Lilly plans to apply for U.S. approval for that use by the end of 2026. The results are not an approval for sleep apnea, and the planned application has not been announced as submitted.
The Lilly release describes ATTAIN-OSA as two independent, randomized, double-blind, placebo-controlled studies lasting 52 weeks. One enrolled 363 adults unable or unwilling to use positive airway pressure, or PAP, therapy; the other enrolled 349 adults already using PAP for at least three months who continued it during the study. The figures are enrollment totals for each study, not the number assigned to the drug alone.
In the study without PAP, the average reduction in apnea-hypopnea index, or AHI, was 21.1 breathing-interruption events per hour with Foundayo versus 4.3 with placebo. In the PAP study, the reductions were 18.3 versus 5.5 events per hour. The release reports percentage reductions of 43.8% versus 6.3% without PAP and 27.5% versus 3.0% with PAP. AHI counts how often breathing stops or becomes shallow during sleep; the company says both studies met the primary endpoint.
Among participants taking Foundayo, 31.5% in the non-PAP study and 19.6% in the PAP study reached the combined category of remission or mild disease. That does not mean those participants were all cured. The release defines remission as fewer than five AHI events per hour and mild disease as five to under 15, with a daytime-sleepiness score of 10 or less. The PAP study’s participants continued their therapy: these results are not a reason to stop PAP or CPAP without a treating clinician’s advice.
The numbers carry an important analysis limit. Lilly says all reported data use the efficacy estimand, which estimates the result had all randomized participants stayed on the assigned intervention for 52 weeks, allowing interruptions or dose changes, without specified additional treatments. Those excluded interventions included starting PAP in the non-PAP group, prohibited sleep-apnea surgery or procedures, and prohibited weight-management treatment. This is not simply an observed outcome for every person who began treatment regardless of discontinuation or other care.
Foundayo participants lost an average of 11.5% of body weight without PAP and 11.2% with PAP, versus 1.8% and 0.9% with placebo. Lilly also reports reduced sleep-apnea-specific oxygen-loss burden and improvements in inflammation and systolic blood pressure. These are sleep and cardiovascular-risk-factor findings, not proof that the medicine prevents heart attacks, strokes or death. The release notes that systolic blood pressure, unlike the other measures, was not controlled for family-wise type 1 error, a safeguard against false-positive findings across multiple tests.
Side effects and treatment persistence matter alongside the benefit. The most common adverse events were gastrointestinal, including nausea, diarrhea, constipation, indigestion and vomiting, generally mild to moderate. Discontinuation because of adverse events was 12.2% with Foundayo versus 3.8% with placebo without PAP, and 6.8% versus 0.6% with PAP. Those differences need to be weighed against the average reductions in breathing interruptions rather than treating the trial as a benefit-only result.
The release’s safety warning says Foundayo may cause thyroid tumors, including thyroid cancer, and must not be used by people with a personal or family history of medullary thyroid carcinoma, or MTC, or by people with Multiple Endocrine Neoplasia syndrome type 2, or MEN2. It also warns against use after a serious allergic reaction to orforglipron or its ingredients, and against combining it with other GLP-1 receptor agonists. Other serious risks in the safety summary include pancreatitis, severe stomach problems, dehydration-related kidney problems, gallbladder problems, allergic reactions and low blood sugar with certain diabetes medicines. A neck lump or swelling, hoarseness, trouble swallowing or shortness of breath should be reported to a healthcare provider.
According to Lilly, Foundayo already has FDA approval for long-term weight management in eligible adults, alongside reduced-calorie diet and increased physical activity; that indication is distinct from the proposed sleep-apnea use. An oral treatment could widen the options considered by adults whose obesity or overweight accompanies sleep apnea, but the next regulatory decision remains ahead. The announcement does not establish an approval date for OSA, long-term outcomes beyond the study period or comparative effectiveness against other medicines. This report relies on Lilly’s release, not an independent review of the AHA presentation or JAMA paper.
JBizNews Desk | Indianapolis, Indiana
© JBizNews.com. All rights reserved. Unauthorized reproduction or redistribution is strictly prohibited.
